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Abstract
Personalised medicine (PM) has the potential to increase therapeutic effectiveness, reduce side effects and lower
cost. The identification of biomarkers predictive of the clinical response to specific treatments in subsets of patients
became reality for a variety of diseases. However, a better understanding of the benefits and limitations needs to be
developed at the level of the general public as well as at the level of an individual patient. The upcoming ability to
characterize each patient from the genetic point of view in a comprehensive manner is believed to have the potential
to transform medicine, thus enabling accurate prognosis as well as a treatment outcome prediction. However, PM
holds both promise and cause for concern. Although PM promises that an individual’s genetic information may be
increasingly used to prioritize medical decision making, it raises in parallel fears and questions as to whether such
use could be inequitable. Thus, there are many thoughts whether the use of individual genetic information in the
delivery of health care can be a cause for concern, as it may lead to genetic discrimination and other problems such
as with employers and private insurance companies. Finally, the main pitfall of predictive tests for complex disease
remains the putative lack of proven medical benefit. A better understanding of the benefits PM will have to be
developed at the level of the general public as well as at the level of an individual patient; which will also reassure
people that their genetic data is used appropriately to choose therapeutic protocols and drugs.
Keywords: Personalized medicine; Pharmacogenetics; Genetic
discrimination; Biomarkers; Ethics
Introduction
Precision or Personalized medicine (PM) proposes to customise
healthcare, with respect to medical decisions, practices, and/or
products by tailoring these to the individual patient. In this context,
genetic testing is often employed for selecting appropriate and optimal
therapies based on a patient’s genetic make-up. PM has the potential to
revolutionize medical care by utilizing an improved understanding of
genetics to allow for better diagnostic tests, greater predictability of
disease course and improved patient safety by selecting not only the
right drug for the right patient but also the proper dosage and timing
to reduce adverse effects. Such achievements have been made possible
by the recent advances of biotechnological sciences generating disease-
relevant molecular information, with the potential for tailoring patient
care. We will limit our discussion to genetics data however, several
other fields (notably all-omics) have massively progressed over the past
few years. And nowadays challenges may lie more in establishing
frameworks for regulating, compiling, and interpreting the influx of
information.
The use of genetic data in PM has first taken off in oncology where
treating malignancies with specific drugs was based on genetic
biomarkers or other tumor characteristics. Thus, the identification of
biomarkers predictive of the clinical response to specific treatments in
subsets of patients allowed PM to be initiated for a few diseases. The
development of PM, apart from the challenges and promises it brings,
raises concerns that should be addressed before its overall vision comes
true. According to the principle of PM, a particular treatment will be
given only to patients that are the most likely to benefit from it. The
possibility to tailor therapies specifically for each patient revealed the
necessity to fill the gap in the awareness and understanding by patients
of the concept involved in PM for them to comprehend why they are
(or not) getting certain treatment.
Genetics in the public eye had a bad reputation mostly linked to
historical facts and eugenics concepts. The development of a
communication campaign by the Human Genome project (http://
en.wikipedia.org/wiki/Human_Genome_Project; www.genome.gov/
12011239; http://plato.stanford.edu/entries/human-genome/) has
greatly contributed to reducing fears and moved the discussion to an
ethical and legal level. Genetic discrimination remains today’s most
obvious general public concern while access to genetics information
hence to PM represents the other side of the conundrum [1]. The
collection, records and use of genetic information had nonetheless
raised major concerns, if not misconceptions related to discrimination
and stigmatization. Legal and ethical concerns mostly revolving
around issue related to genetic discrimination have predominantly
focused around employment or private insurance, suggesting that
there is a need to consider a broader view of genetic discrimination,
departing from simple categorization [2].
Discrimination
Historically, human variation has been classified by assigning
subjects to different races. Any tailoring of medical treatment based on
race is however recipe for failure considering that ethnicity has a poor
relationship to health. Whether states, employers or insurers should be
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allowed to take into account genetically derived information that
reveals an individual's prospects for future disease and incapacity is the
main point of concern. This is perceived to have the potential for
impacting on all sorts of societal and socio-economical factors from
employment to the purchase of health, life or disability insurance. It is
conceivable that employers may claim to have a legitimate financial
interest in genetic data about future potential employees, given that
those at increased risk for a genetic disorder may generate expenses
such as sick days. However, this may further affect decisions with
regards to promotion, provision of additional training, disability pay
and pensions, which are non-ethical even illegal, as there are clear laws
forbidding genetic discrimination in the workplace (ban genetic
discrimination in the workplace) [3].
Health insurance
The other main concern is about using genetic data in relation to
insurance with the fear that genetic information can be used by
insurers to deny, limit or cancel health insurance policies (for example
in the US http://ghr.nlm.nih.gov/handbook/testing/
insurancecoverage). Despite the confidence of the public that genetic
research has brought health benefit, this is nonetheless causing some
patients to refuse to participate in research studies while others refuse
to have any genetic test even when advised to due to a possible genetic
disorder.
Concerns were also voiced when insurers express the willingness to
fund the genomic revolution and any validation required to define
criteria for reimbursement. At this stage, it was still unclear how
companies are navigating their way through the world's regulatory
bodies. It is likely that people would avoid genetic testing because of
fear of losing their policy [3,4]. Insurers have asserted that they would
not perform tests to obtain specific genetic information but argued that
they should be free to use available information, citing the need to
avoid “moral hazard” (the risk that people who know they will become
ill will try to obtain insurance at regular rates) [5].
Taking the example of breast and ovarian cancer, risk counselling
based on a genetic test for the Breast Cancer Risk gene (BRAC-1),
raised concerns about confidentiality and the potential for
discrimination prevented 20-25% of eligible women from undertaking
the test [6]. Analysing the reason for refusing the test, over 50% of
women asked cited concern about insurance discrimination. Although,
example of discrimination based on genetic test results could not be
documented, there have been other negative insurance-related
experiences [7], and legislation was established in several (but not all)
countries [8] (i.e., Germany Genetic Diagnosis Act in 2009) towards
limiting the use of genetic information by insurances companies.
Legal constraints
The debates initiated by the insurance related issues are still
continuing and more laws, bills and agreements have and keep being
produced in response to public pressure, notably in the US [9] with
bills being introduced in many sessions of the Congress (Genetic
Information Non-discrimination in Health Act of 2003, S. 1053, 108th
Cong.) and optimal solutions are still being thought. In Europe, the
regulatory control of genetic testing was enacted in 2008 (Additional
Protocol to the 1997 Convention for the Protection of Human Rights
and Dignity of the Human Being) with regard to the application of
Biology and Genetic Testing in Medicine, for Health Purposes.
Although not currently binding, it represents the first European legal
instrument in this area. The original European Convention on Human
Rights and Biomedicine states, in Article 12, that ‘tests which are
predictive of genetic diseases or which serve either to identify the
subject as a carrier of a gene responsible for a disease or to detect a
genetic predisposition or susceptibility to a disease may be performed
only for health purposes or for scientific research linked to health
purposes, and subject to appropriate genetic counseling’. The
Additional Protocol on genetic testing in 2008 further stated in article
7§1 that ‘a genetic test for health purposes may only be performed
under individualized medical supervision’ [10].
In the context of PM, it is likely that regulatory element will be
needed in the future to optimise the use of such tools. Currently, the
regulation of clinical trials to establish the value of PM is notably
slowed down by an excess of lengthy approval processes. In our
economical context, is it critical to allow PM to develop rapidly,
streamlining approval processes notably as patients stratification
should take all into account previous experience acquired for a
particular drug in a particular disease. The focus on clinical
effectiveness associated with the stratification should be paralleled by
economical gain.
Relatives of patients
Another important concern refers to patient’s relatives, a problem
that cannot be solved easily due to the lack of common views on how
to handle the ethical difficulties involved. In any case, professional
involvement is indicated for any type of genetic discussion involving
minors [11]. Genetic testing for clinical purposed should only take
place through a healthcare provider and with adequate counselling. It
is particularly discouraged to use home-kit genetic testing (available
for certain diseases) to assess a “risk to develop” a disease (see section
below) and notably on children. In addition to the risks of inaccurate
results, inaccurate interpretations, potentially harmful interventions
and alteration in family dynamics will most likely results from this
with negative consequences [12,13]. Furthermore, in the context of PM
tests, it is important to get across the message that a test is only valid
for a certain time in the course of a disease and only reflect a patient’s
history up to that point in time (notably taking in consideration
previously failed treatment options). Such test would therefore not be
suitable for a family member notably if this person has not yet
developed the disease itself even if tested positive in a risk-assessment.
At this stage, lifestyle modification and preventive measures (if
available) are more likely to be effective.
Incidental findings
Incidental findings are information that could have important
impact on patients but that were not the primary reason for
performing the test. Any test that produces genetic information will
tend to produce incidental findings because more may be visible than
what was originally sought. Systematic reviews of the ethical reasons
presented in the literature for and against the disclosure of incidental
findings arising in genetic research contexts were conducted [14]. The
view defended by those favoring disclosure, is that only incidental
findings, that have a confirmed clinical utility (i.e., possibility of
treatment or prevention) should be disclosed to patient by qualified
professionals. A second recommendation related to minors suggested
proceeding with caution especially when using new technologies. It is
also recommended that the number of possible incidental findings be
limited even before genetic testing is carried out.
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Commercial use
PM has the potential to select the right drug for the right patient at
the right time during his/her disease course. A further concern in
using approaches involving modern genetics technology is the attitude
of clinicians, patients and patient organizations as well as of the general
public, regarding the use of genetic or clinical data and bio-banks for
industrial studies. It is the same concerns that those raised by patients
who are very willing to contribute to research that is academic and
“non-commercial” but sometimes more reluctant to allow registers and
bio-banks to be shared with industry. On the other hand, it is also quite
difficult to proceed with the necessary research (notably expensive
clinical trials) proving PM principles in any specific drug/disease study
without the help of the pharmaceutical industry. Regulation for such
collaborations is usually well looked into and it should become less of a
concern and results in the promotion of PM orientated studies.
Medical decisions
For certain diseases the use of genotyping or genetic testing as a
diagnostic tool or the prescription of drugs based on
pharmacogenomic information is expected to become the standard of
care in the near future. Physicians and pharmacists might be subject to
liability if they lack sufficient knowledge of genetics to adequately
interpret diagnostic tests and prescribe appropriate drug. The law in
most countries has yet to establish the standard to which any physician
will be held. Indeed, professionals have a duty to explain the risk of
false-positive and false-negative test results and the implications of
uncertainty of results [15], and in making disclosures, they are legally
held to the high standard of knowledge in their specialty. In light of the
current low level of instruction in genetics that is received in medical
school, PM genetic counsellors might well become a novel specialty.
Ethical
From an ethical point of view, the usual criticism of genetic testing
for disease diagnostic is that there is no proven direct medical benefit
from the test. With complex diseases notably, conclusions can only be
drawn from a genetic test for an individual, if the number of DNA
markers tested positive for association with the disease is very high
because each marker individually contributes very little to the disease.
Psycho-social research has found little evidence that the results of a
genetic test for a disease risk is prompting change behaviour towards
sustained healthy or prevention from patients at high risk of a disease
while there is as little evidence that it is bringing long-term negative,
psychological impact [16].
In the context of PM (i.e., for response to therapy) such test is more
likely to demonstrate direct benefit and therefore should raise less
ethical concerns although it is also important to consider that PM offer
a “chance” to select the right patient for the right drug at the right time
but always with a certain percentage of risk to be wrong in the
prediction of response as well as non-response. Therefore, rules may
need to be established in order not to discriminate patients from
receiving a specific drug due to a predictive test being negative and to
lower any potential risk for inequities raised by the use of PM tools.
Conclusion
To achieve the promises of PM, a better understanding of its
benefits and limitations needs to be developed at the level of the
general public as well as at the level of individual patient. Conceptual,
societal, ethical and cultural aspects of PM briefly reviewed in this
paper, needs to be passed across at several levels involving all actors or
the health system as well as patients and organisations. This will also
reassure people that their genetic data is used properly in combination
with advanced therapeutic protocols and drugs. Classification of
patients according to the influences of genetic and environmental
factors may lead to reliable conclusions about disease’s susceptibility
and clinical response. Thus, by inferring genetic characteristics
obtained from a group of individuals to a single person,
pharmacogenetics will be able to guide clinicians to prescribe the most
appropriate drug. Therefore, patients must be aware of new treatments
and issues concerning their efficacy, safety and potential adverse
reactions, while doctors are expected to base treatment decision on the
best available evidence but also considering the relative cost to benefit
ratio of other available treatments.
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